grant
Genetic and Immuno-inflammatory Drivers of Post-acute Pulmonary Sequelae of SARS-CoV-2
Organization NEW YORK UNIVERSITY SCHOOL OF MEDICINELocation NEW YORK, UNITED STATESPosted 5 Feb 2023Deadline 31 Jan 2028
NIHUS FederalResearch GrantFY20262019 novel corona virus2019 novel coronavirus2019-nCoVAHCPRAHRQAcuteAcute DiseaseAgency for Health Care Policy and ResearchAgency for Healthcare Research and QualityAllelesAllelomorphsAntibodiesAntibody ResponseAutoantibodiesAutoimmuneAutoimmune MechanismAutoimmune ProcessAutomobile DrivingBiological MarkersBlackBlack raceBody TissuesCAT scanCOVID infected patientCOVID patientCOVID positive patientCOVID-19 infected patientCOVID-19 infectionCOVID-19 patientCOVID-19 positive patientCOVID-19 sequelaeCOVID-19 virusCOVID-19 virus infectionCOVID19 infectionCOVID19 patientCOVID19 positive patientCOVID19 virusCT Lung ScreeningCT X RayCT XrayCT imagingCT scanCarbon MonoxideCategoriesCausalityCharacteristicsChronicClinicalClinical DataCoV-2CoV2Computed TomographyCytokine Signal TransductionCytokine SignalingDataDevelopmentDiffusionDiseaseDisorderDysfunctionEthnic OriginEthnicityEtiologyFatigueFecesFibrosing AlveolitisForced Vital CapacityFrequenciesFunctional disorderFutureGeneticGenetic DiversityGenetic PolymorphismGenetic ProcessesGenetic RiskGenetic VariationGenomicsGenotypeGoalsHaplotypesHealthHistoryIFNIL-1IL-1raIL1IL1 febrile inhibitorIL1RNImmune responseImmunochemical ImmunologicImmunologicImmunologicalImmunologicallyImmunologicsImmunomodulationImpairmentIncidenceIndividuals from minorityIndividuals of minorityInfectionInfection ControlInflammatoryInflammatory ResponseInterferonsInterleukin IInterleukin-1Interleukin-1 Receptor AntagonistLack of EnergyLong COVIDLong COVID-19Long coronavirus diseaseLong coronavirus disease 2019Long-Term EffectsLongitudinal StudiesLongitudinal SurveysLung CAT ScanLung CTLung CT scanLung Tissue FibrosisLung symptomLymphocyte-Stimulating HormoneMacrophage Cell FactorMeasuresMinority GroupsMinority PeopleMinority PopulationMinority individualNasopharynxNeighborhoodsNeurocognitiveNon-Polyadenylated RNAOutcomePASCPathogenicityPathway interactionsPatient Outcomes AssessmentsPatient Reported MeasuresPatient Reported OutcomesPatientsPhenotypePhonePhysiologicPhysiologicalPhysiopathologyPlayPopulationPost Acute Sequelae of COVID19Post Acute Sequelae of SARS-CoV-2Post Acute Sequelae of SARS-CoV2Post Acute Sequelae of severe acute respiratory syndrome coronavirus 2Post-Acute Sequelae of SARS-CoV-2 InfectionPost-vaccination infectionProcessProtocolProtocols documentationProxyPulmonary FibrosisPulse OximetryQOLQuality of lifeQuestionnairesRNARNA Gene ProductsRaceRacesRecording of previous eventsResolutionRhinopharynxRibonucleic AcidRisk-associated variantRoleSARS corona virus 2SARS-CO-V2SARS-COVID-2SARS-CoV-2SARS-CoV-2 infected patientSARS-CoV-2 infectionSARS-CoV-2 patientSARS-CoV-2 positive patientSARS-CoV-2 sequelaeSARS-CoV2SARS-CoV2 infectionSARS-associated corona virus 2SARS-associated coronavirus 2SARS-coronavirus-2SARS-related corona virus 2SARS-related coronavirus 2SARSCoV2Severe Acute Respiratory Coronavirus 2Severe Acute Respiratory Distress Syndrome CoV 2Severe Acute Respiratory Distress Syndrome Corona Virus 2Severe Acute Respiratory Distress Syndrome Coronavirus 2Severe Acute Respiratory Syndrome CoV 2Severe Acute Respiratory Syndrome-associated coronavirus 2Severe Acute Respiratory Syndrome-related coronavirus 2Severe acute respiratory syndrome associated corona virus 2Severe acute respiratory syndrome coronavirus 2Severe acute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome related corona virus 2SeveritiesShortness of BreathSocial outcomeSocio-economic statusSocioeconomic StatusStructureSymptomsSyndromeT Helper FactorTelephoneTestingTissuesTomodensitometryTotal Lung CapacityUnited States Agency for Health Care Policy and ResearchUnited States Agency for Healthcare Research and QualityVaccinationVariantVariationVital capacityWalkingWuhan coronavirusX-Ray CAT ScanX-Ray Computed TomographyX-Ray Computerized TomographyXray CAT scanXray Computed TomographyXray computerized tomographyacute COVID-19acute SARS-CoV-2 infectionacute disease/disorderacute disorderacute infectionacute phase of COVID-19acute phase of SARS-CoV-2 infectionadverse sequelae of COVIDadverse sequelae of COVID-19adverse sequelae of coronavirus diseaseadverse sequelae of coronavirus disease 2019after COVID-19 infectionafter SARS-CoV-2 infectionafter SARS-CoV2 infectionafter infection by SARS-CoV-2after severe acute respiratory distress syndrome CoV-2 infectionanakinraautoimmune antibodyautoreactive antibodybio-markersbiologic markerbiomarkerblack patientbreakthrough infectioncatscancausationchronic COVIDchronic COVID-19chronic COVID-19 sequelaechronic complication of COVID-19chronic effect of COVID-19chronic novel coronavirus disease 2019chronic symptomcognitive assessmentcognitive testingcohortcomputed axial tomographycomputer tomographycomputerized axial tomographycomputerized tomographycomputerized tomography lung screeningcoronavirus disease 2019 infected patientcoronavirus disease 2019 infectioncoronavirus disease 2019 patientcoronavirus disease 2019 positive patientcoronavirus disease 2019 viruscoronavirus disease infected patientcoronavirus disease patientcoronavirus disease positive patientcoronavirus disease-19 patientcoronavirus disease-19 viruscoronavirus patientcytokinedeprivationdesigndesigningdevelopmentaldiffuse interstitial pulmonary fibrosisdiffuseddiffusesdiffusingdiffusionsdisease causationdrivingfibrosis in the lungfollowing COVID-19 infectionfollowing SARS-CoV-2 infectionfollowing SARS-CoV2 infectionfollowing infection by SARS-CoV-2following severe acute respiratory distress syndrome CoV-2 infectiongenetic associationgenetic etiologygenetic mechanism of diseasegenome scalegenome-widegenomewidehCoV19historieshost responseidiopathic pulmonary fibrosisimmune modulationimmune regulationimmune system responseimmunologic reactivity controlimmunomodulatoryimmunoregulationimmunoregulatoryimmunoresponseimprovedindexinginfected with COVID-19infected with COVID19infected with SARS-CoV-2infected with SARS-CoV2infected with coronavirus disease 2019infected with severe acute respiratory syndrome coronavirus 2infection with SARS-CoV-2interleukin 1 receptor antagonist proteinlong haul COVIDlong haul COVID-19long haul coronavirus diseaselong haul coronavirus disease 2019long haul sequelae of COVID-19long haul sequelae of coronavirus disease 2019long-hauler COVIDlong-hauler COVID-19long-hauler coronavirus disease 2019long-hauler syndromelong-term COVIDlong-term COVID-19long-term consequence of severe acute respiratory distress syndrome-cov-2 infectionlong-term consequences of COVID-19long-term consequences of SARS-CoV-2 infectionlong-term consequences of coronavirus disease-19long-term coronavirus diseaselong-term coronavirus disease 2019long-term effects of COVID-19long-term effects of coronavirus disease-19long-term health consequences of COVID-19long-term health consequences of SARS-CoV2 infectionlong-term impact of COVID-19long-term impact of SARS-CoV-2 infectionlong-term sequelae of COVID-19long-term sequelae of SARS-CoV-2long-term sequelae of coronavirus disease 2019long-term sequelae of severe acute respiratory syndrome coronavirus 2long-term studylongitudinal outcome studieslongitudinal research studylung computerized axial tomography scanlung computerized tomographylung computerized tomography scanlung fibrosislung functionlymphocyte activating factornCoV2nasopharnygealnon-contrast CTnoncontrast CTnoncontrast computed tomographynovelpathophysiologypathwaypatient infected with COVIDpatient infected with COVID-19patient infected with SARS-CoV-2patient infected with coronavirus diseasepatient infected with coronavirus disease 2019patient infected with severe acute respiratory syndrome coronavirus 2patient stratificationpatient with COVIDpatient with COVID-19patient with COVID19patient with SARS-CoV-2patient with coronavirus diseasepatient with coronavirus disease 2019patient with severe acute respiratory distress syndrome coronavirus 2persistent COVID-19persistent symptompolymorphismpost COVID syndromepost COVID-19 complicationspost COVID-19 related complicationspost COVID-19 sequelaepost COVID-19 syndromepost SARS-CoV-2 infectionpost acute COVID syndromepost acute COVID-19post acute COVID-19 syndromepost acute SARS-CoV-2post acute coronavirus disease 2019post acute coronavirus disease 2019 syndromepost acute coronavirus disease syndromepost acute sequelae following COVID-19post acute severe acute respiratory syndrome coronavirus 2post coronavirus disease 2019 syndromepost coronavirus disease syndromepost-COVIDpost-COVID-19post-acute phases of COVID-19post-acute sequelae following SARS-CoV-2 infectionpost-acute sequelae of COVID-19post-acute sequelae of acute COVID infectionpost-acute sequelae of coronavirus disease 2019post-coronavirus disease 2019previous COVID-19 infectionprevious SARS-CoV-2 infectionprevious SARS-CoV2 infectionprevious severe acute respiratory distress syndrome CoV-2 infectionprimary end pointprimary endpointprior COVID-19 infectionprior SARS-CoV-2 infectionprior SARS-CoV2 infectionprior severe acute respiratory distress syndrome CoV-2 infectionprolonged COVID-19 symptomspulmonarypulmonary functionpulmonary symptomracialracial backgroundracial originresolutionsrisk allelerisk generisk genotyperisk locirisk locusrisk variantsecondary outcomeself reactive antibodysequelae following COVID-19sequelae following SARS-CoV-2 infectionsequelae of COVID-19severe acute respiratory syndrome coronavirus 2 infected patientsevere acute respiratory syndrome coronavirus 2 patientsevere acute respiratory syndrome coronavirus 2 positive patientsocial determinantssocial health determinantssocial rolesocio-economic positionsociodeterminantsocioeconomic positionstoolstratified patienttherapeutic targeturine IL-1 inhibitorurine interleukin 1 inhibitorurine-derived IL1 inhibitor
Description preview
The goal of this proposal will be to study the frequency, chronicity, and etiology of post-acute sequelae of SARS CoV-2 with protocols designed to characterize genetic and immuno-inflammatory factors that influence post-COVID complications. We will establish a cohort of 1200 or more deeply phenotyped SARS CoV-2 patients in order to determine the…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click